COVID-19

Excerpt from the Press Release: “SAN DIEGO, July 16, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study…

Excerpt from the press release: “SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Centivax Inc, the therapeutics spinout of Contract Research Organization Distributed Bio Inc, announced today that their antibody therapeutic protects hamsters from SARS-CoV-2, the COVID-19-causing coronavirus. Confirmed simultaneously at two independent national laboratories, these results provide critical support for the antibody to move to clinical studies to…

Excerpt from the article: “An aerosol-based drug treatment could drastically reduce the number of new coronavirus patients dying from the disease or requiring intensive care, according to preliminary results released by a British biotech firm. In a randomised trial of 100 patients admitted to hospital with COVID-19, those who received an inhaled formula of the…

Excerpt from the press release: MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–Jul. 16, 2020– PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has dosed the first patient in VANGARD, a potentially pivotal Phase 2 clinical trial to evaluate PB1046…

Excerpt from the Press Release: “LA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that as reported by its partner, Biocon Limited, a clinical trial conducted in India by Biocon demonstrated that itolizumab significantly reduced mortality…

Excerpt from the article: “As the scientific community races toward potential treatments for Covid-19, the respiratory illness caused by the novel coronavirus that has now killed at least 116,000 Americans, researchers at Harvard’s Wyss Institute are partnering with institutions across the U.S. on a new project using old materials. The Wyss Institute has signed a…

Excerpt from the press release: “SAN FRANCISCO–(BUSINESS WIRE)–IncellDx announces the patent filing with the USPTO and the Pre-EUA with the FDA for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of a novel coronavirus disease 2019 (COVID-19), is now a global pandemic.…

Excerpt from the article: “Although much has changed in the landscape of clinical trials because of COVID-19, the framework of inspection readiness planning and activities remains the same. It is however crucial to understand how the impacts of COVID-19 play a role in our preparation activities. Our recent Halloran Speaker Series, “Inspection Readiness Framework and…

Excerpt from the article: “Gilead Sciences Inc. is prepping to launch clinical trials of an inhaled form of its Covid-19-fighting drug remdesivir, a version that could expand access to the treatment and keep less-severe patients out of hospitals. Remdesivir is the only drug granted emergency use authorization from the Food and Drug Administration against the…

Excerpt from the press release: “PHILADELPHIA – June 24, 2020 – PRLog — SFA Therapeutics, Inc. is pleased to announce receipt of a “Save Our Start-ups” (SOS) grant to study SFA005 in the treatment of cytokine storm linked to Acute Respiratory Distress Syndrome (ARDS), which has been experienced by patients infected with COVID-19. This grant…